Translation failure and medical reversal

Two sides to the same coin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Translation failure occurs when the results of preclinical, observational and/or early phase studies fail to predict the results of well done (i.e. appropriately controlled, adequately powered, and properly conducted) phase III or randomised clinical trials. Some failures occur when promising basic science findings fail to replicate in human studies, while others happen when promising uncontrolled trial data show an exaggerated effect that vanishes in the setting of a randomised trial. Medical reversals occur when the results of preclinical, observational and/or early phase studies fail to predict the results of subsequent randomized clinical trials, but the practice has already gained widespread acceptance. Oncologic examples include bevacizumab and the use of autologous stem cell transplant in metastatic breast cancer. In a well-intentioned effort to reduce the rate of translation failure, oncologists must be careful that changes to regulatory processes and clinical trial design do not actually work to increase the approval of ineffective compounds. By trying to cure translation failure, we should be careful to avoid medical reversal. The rise of surrogate end-points and role of hard-wired bias in oncology trials suggest that we may be currently ignoring the simple fact that translation failure and medical reversal are two sides to the same coin.

Original languageEnglish (US)
Pages (from-to)197-200
Number of pages4
JournalEuropean Journal of Cancer
Volume52
DOIs
StatePublished - Jan 1 2016

Fingerprint

Numismatics
Randomized Controlled Trials
Phase III Clinical Trials
Stem Cells
Biomarkers
Clinical Trials
Breast Neoplasms
Transplants
Bevacizumab
Oncologists

Keywords

  • End-points
  • FDA approval
  • Hard-wired bias
  • Medical reversal
  • Oncology drugs
  • Randomised trials
  • Regulatory bar
  • Translation failure

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Translation failure and medical reversal : Two sides to the same coin. / Prasad, Vinay.

In: European Journal of Cancer, Vol. 52, 01.01.2016, p. 197-200.

Research output: Contribution to journalArticle

@article{19f16c5fbde14a75bef90250d5c8be6b,
title = "Translation failure and medical reversal: Two sides to the same coin",
abstract = "Translation failure occurs when the results of preclinical, observational and/or early phase studies fail to predict the results of well done (i.e. appropriately controlled, adequately powered, and properly conducted) phase III or randomised clinical trials. Some failures occur when promising basic science findings fail to replicate in human studies, while others happen when promising uncontrolled trial data show an exaggerated effect that vanishes in the setting of a randomised trial. Medical reversals occur when the results of preclinical, observational and/or early phase studies fail to predict the results of subsequent randomized clinical trials, but the practice has already gained widespread acceptance. Oncologic examples include bevacizumab and the use of autologous stem cell transplant in metastatic breast cancer. In a well-intentioned effort to reduce the rate of translation failure, oncologists must be careful that changes to regulatory processes and clinical trial design do not actually work to increase the approval of ineffective compounds. By trying to cure translation failure, we should be careful to avoid medical reversal. The rise of surrogate end-points and role of hard-wired bias in oncology trials suggest that we may be currently ignoring the simple fact that translation failure and medical reversal are two sides to the same coin.",
keywords = "End-points, FDA approval, Hard-wired bias, Medical reversal, Oncology drugs, Randomised trials, Regulatory bar, Translation failure",
author = "Vinay Prasad",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.ejca.2015.08.024",
language = "English (US)",
volume = "52",
pages = "197--200",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Translation failure and medical reversal

T2 - Two sides to the same coin

AU - Prasad, Vinay

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Translation failure occurs when the results of preclinical, observational and/or early phase studies fail to predict the results of well done (i.e. appropriately controlled, adequately powered, and properly conducted) phase III or randomised clinical trials. Some failures occur when promising basic science findings fail to replicate in human studies, while others happen when promising uncontrolled trial data show an exaggerated effect that vanishes in the setting of a randomised trial. Medical reversals occur when the results of preclinical, observational and/or early phase studies fail to predict the results of subsequent randomized clinical trials, but the practice has already gained widespread acceptance. Oncologic examples include bevacizumab and the use of autologous stem cell transplant in metastatic breast cancer. In a well-intentioned effort to reduce the rate of translation failure, oncologists must be careful that changes to regulatory processes and clinical trial design do not actually work to increase the approval of ineffective compounds. By trying to cure translation failure, we should be careful to avoid medical reversal. The rise of surrogate end-points and role of hard-wired bias in oncology trials suggest that we may be currently ignoring the simple fact that translation failure and medical reversal are two sides to the same coin.

AB - Translation failure occurs when the results of preclinical, observational and/or early phase studies fail to predict the results of well done (i.e. appropriately controlled, adequately powered, and properly conducted) phase III or randomised clinical trials. Some failures occur when promising basic science findings fail to replicate in human studies, while others happen when promising uncontrolled trial data show an exaggerated effect that vanishes in the setting of a randomised trial. Medical reversals occur when the results of preclinical, observational and/or early phase studies fail to predict the results of subsequent randomized clinical trials, but the practice has already gained widespread acceptance. Oncologic examples include bevacizumab and the use of autologous stem cell transplant in metastatic breast cancer. In a well-intentioned effort to reduce the rate of translation failure, oncologists must be careful that changes to regulatory processes and clinical trial design do not actually work to increase the approval of ineffective compounds. By trying to cure translation failure, we should be careful to avoid medical reversal. The rise of surrogate end-points and role of hard-wired bias in oncology trials suggest that we may be currently ignoring the simple fact that translation failure and medical reversal are two sides to the same coin.

KW - End-points

KW - FDA approval

KW - Hard-wired bias

KW - Medical reversal

KW - Oncology drugs

KW - Randomised trials

KW - Regulatory bar

KW - Translation failure

UR - http://www.scopus.com/inward/record.url?scp=84949569600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949569600&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2015.08.024

DO - 10.1016/j.ejca.2015.08.024

M3 - Article

VL - 52

SP - 197

EP - 200

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -